XML 33 R8.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Registered shares
Additional paid-in capital
Treasury shares
Retained earnings
Accumulated other comprehensive loss
Beginning of the period (in shares) at Mar. 31, 2021   173,106,000        
Beginning of the period (in shares) at Mar. 31, 2021       4,799,000    
Beginning of the period at Mar. 31, 2021 $ 2,261,789 $ 30,148 $ 129,519 $ (279,541) $ 2,490,578 $ (108,915)
Increase (Decrease) in Shareholders' Equity            
Total comprehensive income 649,305       644,513 4,792
Purchases of registered shares (in shares)       4,607,000    
Purchases of registered shares (412,022)     $ (412,022)    
Sale of shares upon exercise of stock options and purchase rights (in shares)       (410,000)    
Sale of shares upon exercise of stock options and purchase rights 29,649   12,971 $ 16,678    
Issuance of shares upon vesting of restricted stock units (in shares)       (1,137,000)    
Issuance of shares upon vesting of restricted stock units (64,156)   (105,972) $ 41,816    
Issuance of shares for contingent consideration (in shares)       (4,000)    
Issuance of shares from contingent consideration 292   116 $ 176    
Share-based compensation 93,291   93,291      
Cash dividends (159,410)       (159,410)  
End of the period (in shares) at Mar. 31, 2022   173,106,000        
End of the period (in shares) at Mar. 31, 2022       7,855,000    
End of the period balance at Mar. 31, 2022 2,398,738 $ 30,148 129,925 $ (632,893) 2,975,681 (104,123)
Increase (Decrease) in Shareholders' Equity            
Total comprehensive income 368,421       364,575 3,846
Purchases of registered shares (in shares)       7,562,000    
Purchases of registered shares (418,346)     $ (418,346)    
Sale of shares upon exercise of stock options and purchase rights (in shares)       (686,000)    
Sale of shares upon exercise of stock options and purchase rights 28,790   (5,636) $ 34,426    
Issuance of shares upon vesting of restricted stock units (in shares)       (968,000)    
Issuance of shares upon vesting of restricted stock units (29,163)   (68,710) $ 39,547    
Share-based compensation 71,801   71,801      
Cash dividends $ (162,681)       (162,681)  
End of the period (in shares) at Mar. 31, 2023   173,106,000        
End of the period (in shares) at Mar. 31, 2023 13,763,000     13,763,000    
End of the period balance at Mar. 31, 2023 $ 2,257,560 $ 30,148 127,380 $ (977,266) 3,177,575 (100,277)
Increase (Decrease) in Shareholders' Equity            
Total comprehensive income $ 601,218       612,143 (10,925)
Purchases of registered shares (in shares) 4,100,000     7,100,000    
Purchases of registered shares $ (523,751)     $ (523,751)    
Sale of shares upon exercise of stock options and purchase rights (in shares)       (624,000)    
Sale of shares upon exercise of stock options and purchase rights 32,197   (28,314) $ 60,511    
Issuance of shares upon vesting of restricted stock units (in shares)       (994,000)    
Issuance of shares upon vesting of restricted stock units (29,744)   (118,771) $ 89,027    
Issuance of shares for contingent consideration (in shares)       (2,000)    
Issuance of shares from contingent consideration 245   102 $ 143    
Share-based compensation 83,127   83,127      
Cash dividends $ (187,199)       (187,199)  
End of the period (in shares) at Mar. 31, 2024   173,106,000        
End of the period (in shares) at Mar. 31, 2024 19,243,358     19,243,000    
End of the period balance at Mar. 31, 2024 $ 2,233,653 $ 30,148 $ 63,524 $ (1,351,336) $ 3,602,519 $ (111,202)